These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19542396)

  • 61. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis.
    Fretellier N; Idée JM; Guerret S; Hollenbeck C; Hartmann D; González W; Robic C; Port M; Corot C
    Invest Radiol; 2011 Feb; 46(2):85-93. PubMed ID: 20938344
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Nephrogenic systemic fibrosis or kidney failure--how great is the risk?].
    Rofo; 2010 Feb; 182(2):114-5. PubMed ID: 20120045
    [No Abstract]   [Full Text] [Related]  

  • 64. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Update on nephrogenic systemic fibrosis.
    Thomsen HS; Marckmann P; Logager VB
    Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Nephrogenic fibrosing dermatopathy].
    Zelger B
    J Dtsch Dermatol Ges; 2003 Jun; 1(6):428, 430-1. PubMed ID: 16295135
    [No Abstract]   [Full Text] [Related]  

  • 67. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.
    Knobler R; Moinzadeh P; Hunzelmann N; Kreuter A; Cozzio A; Mouthon L; Cutolo M; Rongioletti F; Denton CP; Rudnicka L; Frasin LA; Smith V; Gabrielli A; Aberer E; Bagot M; Bali G; Bouaziz J; Braae Olesen A; Foeldvari I; Frances C; Jalili A; Just U; Kähäri V; Kárpáti S; Kofoed K; Krasowska D; Olszewska M; Orteu C; Panelius J; Parodi A; Petit A; Quaglino P; Ranki A; Sanchez Schmidt JM; Seneschal J; Skrok A; Sticherling M; Sunderkötter C; Taieb A; Tanew A; Wolf P; Worm M; Wutte NJ; Krieg T
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1581-1594. PubMed ID: 28786499
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nephrogenic Systemic Fibrosis.
    Sarwal A; Gnanasekaran I
    Am J Med Sci; 2021 Jan; 361(1):e5-e6. PubMed ID: 32709396
    [No Abstract]   [Full Text] [Related]  

  • 69. [Imaging and renal failure: from inflammation to fibrosis].
    Grenier N
    J Radiol; 2011 Apr; 92(4):323-35. PubMed ID: 21549888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acetazolamide therapy in meningeal involvement of nephrogenic systemic fibrosis.
    Geara AS; El-Imad B; El-Sayegh S
    Intern Med J; 2010 Dec; 40(12):e4-5. PubMed ID: 21260956
    [No Abstract]   [Full Text] [Related]  

  • 71. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis.
    Quatresooz P; Paquet P; Hermanns-Lê T; Piérard GE
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):448-52. PubMed ID: 20485155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Cutaneous manifestations in renal diseases].
    Schmid-Simbeck M; Udvardi A; Volc-Platzer B
    Hautarzt; 2016 Dec; 67(12):960-969. PubMed ID: 27822733
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Perforating osteoma cutis in the setting of longstanding nephrogenic systemic fibrosis.
    Nguyen CV; Boyle AM; Lee RA
    Int J Dermatol; 2015; 54(5):571-2. PubMed ID: 24962809
    [No Abstract]   [Full Text] [Related]  

  • 74. Chronic, dusky, indurated plaques on the legs of a 31-year-old woman.
    Dewan A; Zwerner J; Abraham JL; Boyd A; Zic J
    Clin Exp Dermatol; 2016 Apr; 41(3):328-30. PubMed ID: 26411642
    [No Abstract]   [Full Text] [Related]  

  • 75. Nephrogenic systemic fibrosis: mini-review.
    Mundim JS; Lorena Sde C; Elias RM; Romão Júnior JE
    Clinics (Sao Paulo); 2009 May; 64(5):482-4. PubMed ID: 19488616
    [No Abstract]   [Full Text] [Related]  

  • 76. Absence of human herpes virus-8 (HHV8) in nephrogenic systemic fibrosis.
    O'Donnell PJ; Duke WH; Pantanowitz L
    BMC Res Notes; 2008 Sep; 1():82. PubMed ID: 18799006
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Algorithm-based approach to focal liver lesions in contrast-enhanced ultrasound.
    Leow KS; Kwok CY; Low HM; Lohan R; Lim TC; Low SCA; Tan CH
    Australas J Ultrasound Med; 2022 Aug; 25(3):142-153. PubMed ID: 35978727
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.
    Kanakia S; Toussaint J; Kukarni P; Lee S; Chowdhury SM; Khan S; Mallipattu SK; Shroyer KR; Moore W; Sitharaman B
    Graphene Technol; 2016 Dec; 1(1):17-28. PubMed ID: 28261636
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines.
    Chiorean L; Tana C; Braden B; Caraiani C; Sparchez Z; Cui XW; Baum U; Dietrich CF
    Med Princ Pract; 2016; 25(5):399-407. PubMed ID: 27318740
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Radiological considerations in von Hippel-Lindeau disease: imaging findings and the review of the literature.
    Apaydin M; Varer M; Oztekin O
    Radiol Oncol; 2010 Sep; 44(3):164-7. PubMed ID: 22933910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.